FBLG vs. LXEO, IKT, ALEC, EPRX, BDTX, KRRO, FTLF, NKTX, GLSI, and TARA
Should you be buying FibroBiologics stock or one of its competitors? The main competitors of FibroBiologics include Lexeo Therapeutics (LXEO), Inhibikase Therapeutics (IKT), Alector (ALEC), Eupraxia Pharmaceuticals (EPRX), Black Diamond Therapeutics (BDTX), Korro Bio (KRRO), FitLife Brands (FTLF), Nkarta (NKTX), Greenwich LifeSciences (GLSI), and Protara Therapeutics (TARA). These companies are all part of the "pharmaceutical products" industry.
FibroBiologics vs. Its Competitors
Lexeo Therapeutics (NASDAQ:LXEO) and FibroBiologics (NASDAQ:FBLG) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, community ranking, institutional ownership, dividends, risk, profitability, media sentiment and valuation.
FibroBiologics has lower revenue, but higher earnings than Lexeo Therapeutics. FibroBiologics is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Lexeo Therapeutics presently has a consensus price target of $18.50, suggesting a potential upside of 352.32%. FibroBiologics has a consensus price target of $13.00, suggesting a potential upside of 1,367.77%. Given FibroBiologics' stronger consensus rating and higher possible upside, analysts plainly believe FibroBiologics is more favorable than Lexeo Therapeutics.
In the previous week, FibroBiologics had 2 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 4 mentions for FibroBiologics and 2 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 1.77 beat FibroBiologics' score of 0.64 indicating that Lexeo Therapeutics is being referred to more favorably in the media.
FibroBiologics' return on equity of 0.00% beat Lexeo Therapeutics' return on equity.
60.7% of Lexeo Therapeutics shares are held by institutional investors. 5.3% of Lexeo Therapeutics shares are held by insiders. Comparatively, 20.0% of FibroBiologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Lexeo Therapeutics received 15 more outperform votes than FibroBiologics when rated by MarketBeat users. Likewise, 100.00% of users gave Lexeo Therapeutics an outperform vote while only 93.33% of users gave FibroBiologics an outperform vote.
Lexeo Therapeutics has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500. Comparatively, FibroBiologics has a beta of -0.8, meaning that its stock price is 180% less volatile than the S&P 500.
Summary
Lexeo Therapeutics beats FibroBiologics on 9 of the 16 factors compared between the two stocks.
Get FibroBiologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FBLG and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FBLG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
FibroBiologics Competitors List
Related Companies and Tools
This page (NASDAQ:FBLG) was last updated on 6/12/2025 by MarketBeat.com Staff
